A
Athos therapeutics
Pioneering the Development of Artificial Intelligence-based Precision Therapeutics for Chronic Inflammatory Diseases
About Athos therapeutics
Athos Therapeutics, a clinical-stage biotechnology company founded in 2019, is focused on developing small-molecule precision therapeutics for immune-mediated diseases and cancer. The company was established by a team with extensive experience in biotechnology and academia: Dimitrios Iliopoulos, Allan J. Pantuck, and Michael Jung. Iliopoulos, the President and CEO, has a background that merges academic research at Harvard and UCLA with business acumen, holding an MBA and certificates in finance, M&A, and AI. His journey from growing up in Greece to becoming a tenured professor at UCLA and now a biotech entrepreneur reflects his long-standing goal of developing new therapies for patients. Pantuck, the Chairman and Chief Medical Officer, is a co-founder of Kite Pharma (acquired by Gilead) and a Professor of Urology at UCLA, bringing deep clinical and regulatory expertise. Jung is a distinguished professor at UCLA and a renowned medicinal chemist behind multi-billion-dollar FDA-approved drugs.
The company's business model centers on its proprietary AI-driven drug discovery platform. This platform integrates multi-omics data from a vast repository of over 35,000 patient samples, sourced through collaborations with institutions like the Cleveland Clinic. By applying machine learning algorithms to this complex biological data, Athos identifies novel drug targets and develops precision small-molecule inhibitors. This technology-first approach aims to accelerate the drug development process, as evidenced by their lead program moving from concept to clinical trial in under four years. The company generates value through the discovery and clinical development of its pipeline assets, with a business strategy geared towards partnerships, licensing, and eventual commercialization of its therapies.
Athos' core product is its advanced drug discovery platform, which comprises several components: RHEA for automated transcriptomics, TETHYS for autonomous proteomics, and DIONE, a deep machine learning framework for patient subtyping. This integrated system, now called "Athos Omics AI," analyzes genetic, protein, and metabolite data to uncover the molecular basis of complex diseases. The platform's primary output is a pipeline of novel drug candidates. The lead asset, ATH-063, is an orally administered small molecule developed for Inflammatory Bowel Disease (IBD) that recently completed a successful Phase 1 clinical trial. The pipeline also includes candidates for other autoimmune diseases like lupus, atopic dermatitis, and Sjögren's syndrome, as well as various cancers, including acute myeloid leukemia (AML). The company's unique selling point is its ability to stratify patients into molecular subtypes, enabling the development of targeted therapies for specific patient populations who are unlikely to respond to existing treatments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 85.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotechnology, Drug Development, Core AI, Precision Medicine, Spinout, Biotech and Pharma, Techbio
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest May 2023
- Capital deployed
- $26M
- Preferred round
- SERIES D
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2024 | $35M | $140M | Undisclosed | ↗ |
| SERIES AOther financing | Nov 2021 | $15M | $60M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Athos therapeutics is 3.1K monthly website visits, down 11.4% over the last three months. Athos therapeutics's team grew 8.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Athos therapeutics in the Torrance ecosystem
The Athos therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
University of California, Los Angeles
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Athos therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Athos therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









